cyrilzakka/clinical-trials huggingface dataset:
Nifedipine Versus Magnesium Sulfate for Prevention of Preterm Labor in Symptomatic Placenta Previa

Antepartum hemorrhage is defined as bleeding from or within the female genital tract, occurring from 28+0 weeks of pregnancy and till delivery of the fetus. it occurs in 3-5% of pregnancies and is an important cause of perinatal and maternal morbidity and mortality worldwide

There are many tocolytic agents may have a role in conservative management of placenta previa such as magnesium sulfate, calcium channel blockers and β-sympathormimetics. In 2004 Sharma suggests that ritodrine hydrochloride in patients with symptomatic placenta previa tends to prolong the pregnancy and result in an increase in birth weight of the babies without causing any adverse effect on the mother and fetus

Eligibility Criteria:
Inclusion Criteria:

* Estimated gestational age : between 28 weeks and 37 week's gestation
* Confirmed Placenta previa; either major or minor degrees.
* Placenta previa with preterm uterine contractions

Exclusion Criteria:

* Severe attack of bleeding requiring an immediate intervention.
* Fetal heart rates instability or non-reassuring tracing
* Intrauterine fetal death or major fetal anomalies.
* If associated with abruptio placentae
* Patients with known bleeding disorders or on anticoagulant therapy
* Patients with severe medical disorders as myasthenia gravis documented magnesium toxicity.
Efficacy of Bilateral Stimulation With Task-oriented Training in Improving Lower Limb Motor Functions in Patients With Stroke

This proposed study aims to compare the effects of unilateral and bilateral transcutaneous electrical nerve stimulation (TENS). It will compare the effectiveness of bilateral TENS + task-oriented training (TOT) with unilateral TENS+TOTin improving muscle strength, co-ordination, dynamic standing balance, walking performance, and functional mobility in patients with chronic stroke.

The null hypothesis will be that bilateral TENS+TOT and unilateral TENS+TOT are not significantly different in promoting the recovery of these functions.

This proposed study aims to compare the effects of unilateral and bilateral transcutaneous electrical nerve stimulation (TENS). It will compare the effectiveness of bilateral TENS + task-oriented training (TOT) with unilateral TENS+TOTin improving muscle strength, co-ordination, dynamic standing balance, walking performance, and functional mobility in patients with chronic stroke.

The null hypothesis will be that bilateral TENS+TOT and unilateral TENS+TOT are not significantly different in promoting the recovery of these functions.

Eligibility Criteria:
Inclusion Criteria:

* Subjects will be recruited from local self-help groups through poster advertising. \\
* Subjects will be included if they (1) are between 55 and 85 years of age
* Have been diagnosed with ischaemic brain injury or intracerebral hemorrhage by MRI or computed tomography within the previous 1 to 10 years
* Are able to walk 3 metres independently with or without a walking aid
* Are able to score \> 6 out of 10 on the abbreviated mental test
* Are able to follow instructions and give informed consent
* Have no skin allergy which would prevent electrical stimulation.

Exclusion Criteria:

* Subjects will be excluded if they have any additional medical, cardiovascular or orthopedic condition that would hinder proper treatment or assessment
* Use a cardiac pacemaker
* Have receptive dysphasia
* Have significant lower limb peripheral neuropathy (e.g. diabetic polyneuropathy)
* Are involved in drug studies or other clinical trials.
Nebulized Magnesium Sulfate and Sildenafil for Persistent Pulmonary Hypertension of Newborn

The aim of this study is to evaluate the effectiveness of nebulized magnesium sulfate combined with sildenafil citrate, compared with sildenafil citrate alone, in treating neonates with severe persistent pulmonary hypertension on mechanical ventilation.

Persistent pulmonary hypertension of newborn (PPHN) is a serious condition that results from failure of the normal postnatal circulatory transition and is associated with significant mortality and morbidity. Advanced medical treatment, such as inhaled nitric oxide (iNO), high-frequency ventilation (HFV), and extracorporeal membrane oxygenation (ECMO) are commonly not available in developing countries. Intravenous magnesium sulfate has been shown to alleviate pulmonary hypertension but is associated with systemic hypotension and is less effective compared with iNO and sildenafil. Nebulized magnesium sulfate has been reported to be more effective and safer compared with intravenous magnesium sulfate in treating neonates with PPHN on mechanical ventilation. Combined nebulized magnesium and sildenafil has been studied in a small trial on spontaneously breathing neonates with PPHN but not on those connected to mechanical ventilation.

The aim of this study is to evaluate the effectiveness of nebulized magnesium sulfate combined with sildenafil citrate, compared with sildenafil citrate alone, in treating neonates with severe PPHN on mechanical ventilation. We hypothesize that neonates with severe PPHN connected to mechanical ventilation could benefit from taking continuous nebulization of magnesium sulfate combined besides sildenafil.

Eligibility Criteria:
Inclusion Criteria:

* Gestational age ≥ 36 weeks
* Birth weight between 2.5 and 4 kg.
* Post-natal age between 6 and 72 hours.
* PPHN confirmed by echocardiography
* Oxygenation index (OI) \> 30 on two occasions at least 15 minutes apart
* Connected to Mechanical Ventilation

Exclusion Criteria:

* Failure to obtain informed consent
* Newborns to mothers who received magnesium sulfate within 48 hours before labor.
* Congenital heart diseases, other than patent ductus arteriosus and foramen ovale.
* Major congenital anomalies (including congenital diaphragmatic hernia and lung hypoplasia).
* Prior need for cardiopulmonary resuscitation.
* Mean arterial blood pressure (MABP) \< 35 mmHg despite therapy with volume infusions and vasoactive inotropes.
* Impaired kidney function.
* Prior administration of pulmonary vasodilators.
* Gastrointestinal intolerance or bleeding
Pulmonary Vascular Changes in Early Chronic Obstructive Pulmonary

The Multi-Ethnic Study of Atherosclerosis (MESA) - Chronic Obstructive Pulmonary Disease (COPD) Study aims to characterize the pulmonary vascular changes and their biology in early COPD using imaging, gene expression profiling and peripheral cellular measures.

Chronic Obstructive Pulmonary Disease (COPD) is the third leading cause of death in the US and will soon replace stroke as the third leading cause.

Translation of promising biological hypotheses of COPD pathogenesis to human populations that may lead to new therapies is urgently needed. The vascular hypothesis of COPD was articulated almost 50 years ago. Bench research on endothelial dysfunction in COPD is evolving rapidly and has shown that acrolein in cigarette smoke causes endothelial apoptosis and endothelial apoptosis is directly implicated in COPD pathogenesis. Clinical studies on endothelial dysfunction and vascular changes in COPD are limited.

The proposed study is a longitudinal study of smokers nested among the MESA-Lung (AAAA7791) and EMphysema and Cancer Action Project (EMCAP) Studies (AAAA6484), which together provide a well-defined cohort of 4,617 participants with prior spirometry and CT measures.

The Multiethnic Study of Atherosclerosis - Chronic Obstructive Pulmonary Disease (MESA COPD Study) has two main scientific purposes:

1. characterize the pulmonary vascular changes in COPD and their biology, and
2. propose novel pathways for new therapies in COPD.

MESA COPD is a longitudinal study of smokers nested within the MESA-Lung and EMCAP cohorts of 360 participants (160 cases with mild, 60 cases with moderate and 40 cases with severe COPD and 100 controls) who will be phenotyped with magnetic resonance (MR) pulmonary angiography, pulmonary function testing, full-lung CT scans, serum Vascular Endothelial Growth Factor (VEGF), cell assays and gene expression profiling. MESA COPD Study will contribute improving the knowledge of early changes in COPD that may lead to novel disease-modifying medical therapies and preventative strategies.

Eligibility Criteria:
Inclusion Criteria:

* age 50-79 years at time of enrollment
* ever smokers (10 or more pack-years)
* participation in MESA or EMCAP studies

Exclusion Criteria:

* clinical cardiovascular disease (left congestive heart failure (CHF), valve disease, coronary artery disease (CAD), stroke, or congenital heart disease),
* asthma, pulmonary embolism or lung disease other than COPD,
* weight \> 300 lbs,
* chronic renal insufficiency (\[estimated glomerular filtration rate (eGFR)\] \< 45 mL/min/1.73 m2),
* atrial fibrillation, and
* contraindications to magnetic resonance imagine (MRI), gadolinium, albuterol or spirometry testing.
Evaluation of MM-151 + Nal-IRI + 5-FU + Leucovorin in RAS/RAF Wild-type Metastatic Colorectal Cancer

A phase 1b/2a study evaluating the combination of MM-151 + nal-IRI + 5-FU + Leucovorin in RAS/RAF wild-type Metastatic Colorectal Cancer.

Part 1: Patients will be enrolled to determine the maximum tolerated dose, safety and tolerability of MM-151 + nal-IRI + 5-FU + LV in patients with mCRC that are RAS/RAF wild-type.

Part 2: Patients will be enrolled at the maximum tolerated dose of MM-151 in combination with nal-IRI + 5-FU + LV to characterize initial efficacy in conjunction with levels of irinotecan and SN-38 measured in tissue.

Eligibility Criteria:
Inclusion Criteria:

* Patients must be greater than 18 years of age
* Patients must be able to provide informed consent
* Patients must have KRAS/NRAS/BRAF wild-type colorectal cancer
* Willing to abstain from sexual intercourse or to use an effective form of contraception during the study and for 120 days following the last dose of any study therapy). This applies to women of childbearing potential as well as fertile men and their partners

Exclusion Criteria:

* Patients who have had previous pelvic radiation treatment
* Patients who are pregnant or lactating
* Patients who have untreated (primary) or uncontrolled Central Nervous System (CNS) (primary or metastatic) malignancies; patients with CNS metastases who have undergone surgery or radiotherapy or who have been on a stable dose of corticosteroids for at least 2 weeks and whose disease is stable prior to the first scheduled day of dosing will be eligible for the trial.
* History of any second malignancy in the last 3 years; patients with prior history of in-situ cancer or basal or squamous cell skin cancer are eligible.
* Patients who have received other recent antitumor therapy including any standard chemotherapy or radiation within 14 days and bevacizumab within 28 days (and having passed the time of any actual or anticipated toxicities) prior to the first scheduled dose of the study treatment
Confirmatory Study of DSP-5423P in Patients With Schizophrenia

The primary objective of the study is to evaluate the efficacy of DSP-5423P compared with placebo in patients with schizophrenia.


Eligibility Criteria:
Inclusion Criteria:

* Patients who have schizophrenia diagnosed by DSM-5, diagnostic criteria
* Patients who are aged 18 years or older at informed consent
* Patient understands the objectives and procedures of the study and who provide written voluntarily consent to participate in the study, etc.

Exclusion Criteria:

* Patients who fall under a contraindication listed in the blonanserin (LONASEN) package insert
* Patients with Parkinson disease
* Patients who previously received blonanserin, etc.
Evaluating the Effectiveness of Paclitaxel-eluting Balloons for Below-the-knee Angioplasty in Patients With Critical Limb Ischemia

to evaluate the the effectiveness of paclitaxel-eluting balloon for below-the-knee angioplasty in terms of restenosis at 12 months


Eligibility Criteria:
Inclusion Criteria:

* age\>18 years
* angiographic stenosis\>50% or occlusion of one below-knee vessel

Exclusion Criteria:

* allergy to Paclitaxel
* contraindication for combined antiplatelet treatment
* life expectancy \<1 year
* hypersensitivity or contraindication to one of the study drugs
* lack of consent
* need for amputation
MiCo - Mirena or Conventional Medical Treatment for Menorrhagia

The aim of this prospective, non-interventional post-marketing surveillance study is to obtain data on safety and efficacy of Mirena in treatment of heavy menstrual bleeding (Menorrhagia) under daily-life treatment conditions.For each patient, an initial visit and one to three follow-up visits after about 3, 6 and 12 months will be documented by the treating physician on the case report form. Observations include the patient's demographic parameters (date of birth, height, weight, race and smoking habits), previous contraceptives and menorrhagia treatment, gynaecological history, baseline menstruation, result of insertion, concomitant medications and diseases as well as menorrhagia symptoms. Overall treatment success will be evaluated at the end of treatment including number of weeks until improvement and reduction of menstrual bleeding with respect to duration and severity, and patient's satisfaction.

The "MiCo - Mirena or conventional medical treatment for menorrhagia" study consist of two parts, MiCo Asia-Pacific and MiCo MA0901 (Rest of World).

Data from both parts will be analysed in separate pools as well as in a global pool. The trial alias are IMPACT Nos. 14697 (NCT00864136), 14536.

Eligibility Criteria:
Inclusion Criteria:

* Women between the ages of 18-45 (inclusive) not intending to become pregnant during the next year
* Women complaining of heavy menstrual bleeding over several consecutive cycles
* Women without structural or histological abnormality of the uterus, or with fibroids less than 3 cm in diameter which are causing no distortion of the uterine cavity (eligible for pharmaceutical treatment according to the NICE guideline 2007)
* Informed consent (where required by laws or regulations)

Exclusion Criteria:

* The contraindications and warnings of the respective Summary of Product Characteristics (Mirena®, combined oral contraceptives, oral/injectable progestogens, non-steroidal anti-inflammatory drug, or anti-fibrinolytic agent) must be followed.
* Women taking hormone replacement therapy
* Women with symptoms such as intermenstrual or post-coital bleeding, unless an endometrial biopsy has been performed and pathology excluded
* Women with fibroids that are palpable abdominally or who have intra-cavity fibroids and/or whose uterine length as measured at ultrasound or hysteroscopy is greater than 12 cm (NICE guideline 2007)
* Women on anticoagulative therapy or other treatment (including e.g. Copper IUD use) known to cause menorrhagia
Pilot Study on the Evaluation of Irreversible Electroporation Technique in Infiltrating Perihilar Cholangiocarcinoma

The aim of the study is to evaluate the feasibility of irreversible electroporation in the treatment of locally advanced cholangiocarcinoma. This technique would allow to treat the unresectable part of the tumor to make it more accessible for a secondary surgery.


Eligibility Criteria:
Inclusion Criteria:

* 18-75 years old
* Patient with infiltrating cholangiocarcinoma of the gallstone convergence considered as unresectable on the pre-operative imaging data performed during the month preceding inclusion, and in multidisciplinary consultation meeting specialised in digestive oncology
* Histologically (or cytologically) proven tumor of less than 4 cm of the largest diameter
* World Health Organization Performance Index 0 or 1
* No history of other cancer, except baso-cellular skin carcinoma or epidermoid cervix cancer or any other cancer in complete remission for more than 3 years
* No prior radiotherapy for cholangiocarcinoma
* Biological analyses performed during the month preceding inclusion : hepatic enzymes (AST and ALT \<3N), preserved renal function (creatinine clearance according to Modification of the Diet in Renal Disease \>50ml/min); bilirubin \<3N; bile drainage must be correct with a bilirubin below 3N , with or without drainage/prothesis, hemoglobin \>9g/dL, leucocytes \>3500/mm3, platelets \>75000/mm3, prothrombin rate \>70%
* Signature of the informed consent

Exclusion Criteria:

* Cholangiocarcinoma of more than 4cm diameter or resectable according tio the imaging data
* Severe and/or uncontrolled (cardiac, pulmonary, renal, liver decompensation...) visceral failure, in the 6 months preceding the study
* Visceral metastases or peritoneal carcinosis
* History of cancers except if remission for more than 3 years, in-situ cancer, epidermoid or baso-cellular cancer
* Metal biliary prothesis non extractable
* Patient with history of epileptic events
* History of myocard infarction for less than 6 months
* Unstabilised coronary disease for at least 6 months
* Cardiac rhythm trouble or QT space above 550ms without treatment
* Patient eligible to liver transplant
* Patient naive of chemiotherapy
* Patient with a pacemaker, an implanted automatic defibrillator or an automatic electronic device or an electronic device with metal pieces
* Patient with contra-indication to the use of NanoKnife system
* History of hypersensitivity to gadolinium or to iodized contrast product not allowing a suitable radiologic monitoring
* Refusal or language or psychic incapacity to sign the informed consent
* Subject who cannot submit to the constraints of the protocol (subjects for which an MRI or a scan is contra-indicated, claustrophobic subjects, non cooperative or not able to come to the follow-up visits)
* Concomitant participation to another study
* Persons benefiting from enhanced protection, namely minors, persons deprived of their liberty by a judicial or administrative decision, adults under legal protection.
* Women at age to procreate and not using effective contraception
Evaluation of the Efficacy and Safety of Methylprednisolone Combined With the JAK Inhibitors in the Treatment of Toxic Epidermal Necrolysis

To evaluate the efficacy and safety of methylprednisolone combined with the JAK inhibitor abxitinib and tofacitinib in the treatment of toxic epidermal necrolysis


Eligibility Criteria:
Inclusion Criteria:

1. Age 18 and above.
2. Diagnosed with SJS/TEN according to the Registry of Severe Cutaneous Adverse Reactions (RegiSCAR) criteria.
3. Liver and kidney function is within acceptable ranges.
4. Blood parameters, including complete blood count, coagulation function, and platelet count, are within acceptable ranges.
5. Patients must sign an informed consent form, understanding the risks and potential benefits of the treatment.
6. Patients need to be capable of participating in follow-up visits and treatment plans.

Exclusion Criteria:

1. History of allergy to JAK inhibitors.
2. Pregnant or breastfeeding women.
3. Severe infectious conditions.
4. History of central nervous system demyelinating diseases.
5. History of lymphoproliferative diseases.
6. Active and latent tuberculosis.
7. HIV carriers with a CD4+ T cell count lower than (\<200/mL).
8. Active HBV/HCV infection.
9. Coagulation disorders or a tendency for thrombosis.
10. Significant abnormalities in blood routine indicators.
11. Liver or kidney dysfunction.
HEALTHCARE STUDENTS' ATTITUDES TOWARDS PATIENTS WITH CHRONIC PAIN

Researchers studied the attitude towards patients with chronic pain, it is a very important issue for the literature. The prevalence of chronic pain is very high in the world, however, patients with chronic pain state at every opportunity that patients are not sufficiently understood and stigmatized by healthcare professionals. In this article, researchers studied the validity and reliability of the scale of the attitude of healthcare professionals towards their patients with chronic pain in students studying in the field of health (medicine, physical therapy and rehabilitation, nursing). Researchers found that the Healthcare Professionals' Attitudes towards Patients with Chronic Pain Scale was valid and reliable in healthcare students. Thanks to this scale, students' attitudes towards patients with chronic pain will be measured, and an idea will be gained about the student's deficiency.


Eligibility Criteria:
Inclusion Criteria:

Medicine, nursing, and physical therapy and rehabilitation students in their final year, With internet access, Who want to participate in the study.

Exclusion Criteria:

Medicine, nursing, and physical therapy and rehabilitation 1st, 2nd, and 3rd year undergraduate students Not wanting to participate in the research
Breath Analysis in Healthy Controls

The purpose of this study is to detect a specific profile of breath in healthy subjects by an untargeted metabolomic study using exhaled breath analysis by mass spectrometry.


Eligibility Criteria:
Inclusion Criteria:

1. Normal spirometry (forced expiratory volume in 1 second (FEV1) \> 80%, forced vital capacity (FVC) \> 80%, FEV1/FVC \> 70%.).
2. Age between 18 and 90 years at study entry.

Exclusion Criteria:

1. Presence of an active malignancy.
2. Presence of any lung disease (e.g. asthma, chronic obstructive pulmonary disease (COPD), sarcoidosis)
3. Acute inflammatory disease (e.g. common cold) within the last 6 weeks.
4. Acute or chronic hepatic disease.
5. Renal failure or renal replacement therapy.
Distribution Circumferential Versus Non Circumferential of Mepivacaine in the Median and Ulnar Nerves

1. Evaluation of the efficacy of the circumferential versus non circumferential distribution of mepivacaine around the median and ulnar nerves.
2. Evaluation the onset of action of mepivacaine in circumferential versus non circumferential distribution around the median and ulnar nerves.
3. Spread of mepivacaine after injection guided by ultrasonography.
4. Complications of both anesthetic techniques in postoperative time.


Eligibility Criteria:
Inclusion Criteria:

* Scheduled patients for surgery of carpal tunnel including patients in ASA I-III status, without exclusion criteria. The principal investigator study and/or other designated site staff will obtain written informed consent from all research patients.

Exclusion Criteria:

* Abnormal bleeding, infection in the punction side, allergy or other problems with the medication of the study, muscular or nerve diseases, patients \< 18 years old, pregnancy, cognitive disease or reject of the patient
Biomarker Identification for Bladder Cancer Patients

To develop a simple blood and urine test that we would perform before patients start their treatment to predict the risk that their bladder cancer might come back. To develop this test the investigators plan to analyze blood, urine and cancer tissue from bladder cancer patients and follow them closely during and after treatment. This will include looking for changes in proteins and genes that might play a role in bladder cancer biology. The investigators will then compare the information obtained from the studies of blood, urine and cancer tissue between patients that are cured and those whose cancer comes back. The knowledge about these differences between patients can then potentially be used to develop a blood or urine test to tell us who has a high risk for having bladder cancer come back.


Eligibility Criteria:
Inclusion Criteria:

* Adult patients ≥18 years old.
* Patients suspected, clinically diagnosed, or histologically diagnosed bladder cancer.
* Patients undergoing cystoscopy without cancer suspicion.
* Ability to give an informed consent.

Exclusion Criteria:

* Patients receiving concurrent therapy for a second malignancy.
* \< 18 years old.
* Inability to give an informed consent.